Tirzepatide (LY3298176) is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. This peptide compound demonstrates significant potential in metabolic research, particularly in studies related to glycemic control and weight management.
The molecular structure of tirzepatide enables simultaneous activation of both GIP and GLP-1 receptors, creating a synergistic effect that may offer advantages over single-receptor agonists. Research indicates this dual mechanism may enhance insulin secretion while suppressing glucagon release in a glucose-dependent manner.
Our facility produces high purity tirzepatide under strict quality controls, ensuring batch-to-batch consistency for research applications. The product is synthesized using advanced peptide technology and undergoes comprehensive analytical testing.
Important Note: This product is intended for laboratory research purposes only. It is not for human consumption or diagnostic use. Researchers should handle all peptide compounds following appropriate safety protocols.